Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 96

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 96
---
 if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days; |

| ● | if we notify any applicable trustee that we wish to terminate that global security; or |

| ● | if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. |

The applicable prospectus supplement may also
list additional situations for terminating a global security that would apply only to the particular series of securities covered by the
applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible
for deciding the names of the institutions that will be the initial direct holders.

<div align='center'>33

PLAN OF DISTRIBUTION</div>

We may sell the securities from time to time pursuant
to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a combination of these methods.
We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute
securities from time to time in one or more transactions:

| ● | at a fixed price or prices, which may be changed; |

| ● | at market prices prevailing at the time of sale; |

| ● | at prices related to such prevailing market prices; or |

| ● | at negotiated prices. |

A prospectus supplement or supplements (and any
related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities,
including, to the extent applicable:

| ● | the name or names of the underwriters, if any; |

| ● | the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale; |

| ● | any options under which underwriters may purchase additional securities from us; |

| ● | any agency fees or underwriting discounts and other items constituting agents’ or underwriters’ compensation; |

| ● | any public offering price; |

| ● | any discounts or concessions allowed or reallowed or paid to dealers; and |

| ● | any securities exchange or market on which the securities may be listed. |

Only underwriters named in the prospectus supplement
will be underwriters of the securities offered by the prospectus supplement.

If underwriters are used in the sale, they